← Search & browse all drugs

omoconazole

D01AC13

Forms & Strengths

Vaginal cream: 1%
Vaginal suppositories / capsules: 150 mg, 300 mg
Topical cream/spray: 1%

Adult Dosing

Vulvovaginal candidiasis: 150 mg vaginal suppository daily for 3 days, or 300 mg as a single dose, or 1% cream applied intravaginally for 5-7 days.
Dermatomycoses (topical): Apply 1% cream or spray to affected areas 1-2 times daily for 2 to 4 weeks.

Pediatric Dosing

Safety and efficacy in pediatric patients under 12 years have not been extensively established.
Topical use in adolescents (>=12 years): Same as adult topical dosing.

Indications

Treatment of vulvovaginal candidiasis
Topical treatment of superficial dermatomycoses (tinea corporis, tinea cruris, tinea pedis, cutaneous candidiasis)

Mechanism of Action

Imidazole antifungal agent that inhibits lanosterol 14-alpha-demethylase, an enzyme dependent on cytochrome P450.
Impairs biosynthesis of ergosterol, leading to increased cellular permeability, leakage of essential intracellular components, and fungal cell lysis.

Contraindications

Hypersensitivity to omoconazole, other imidazole derivatives, or any excipients in the formulation
First trimester of pregnancy (for systemic or vaginal formulations where systemic absorption is a concern, unless strictly necessary)

Adverse Reactions

Local application site reactions (burning, stinging, erythema, pruritus)
Contact dermatitis or allergic skin reactions
Mild vaginal irritation or burning sensation (with vaginal formulations)

Drug Interactions

Potential interaction with latex contraceptives (vaginal cream/suppositories may damage latex condoms and diaphragms, reducing efficacy)
Minimal systemic absorption from topical and vaginal routes minimizes significant systemic drug-drug interactions (e.g., CYP3A4 inhibitors/substrates), though theoretical interactions with strong CYP inhibitors/inducers exist with high systemic levels.

Curated Content: Needs Vetting Before Put to Clinical Use